Avalyn Pharma Inc.
AVLN
$30.71
$1.735.97%
NASDAQ
| 03/31/2026 | |||||
|---|---|---|---|---|---|
| Revenue | -- | ||||
| Total Other Revenue | -- | ||||
| Total Revenue | -- | ||||
| Cost of Revenue | -- | ||||
| Gross Profit | -- | ||||
| SG&A Expenses | 47.78% | ||||
| Depreciation & Amortization | -- | ||||
| Other Operating Expenses | -- | ||||
| Total Operating Expenses | 49.12% | ||||
| Operating Income | -49.12% | ||||
| Income Before Tax | -53.51% | ||||
| Income Tax Expenses | -- | ||||
| Earnings from Continuing Operations | -53.51% | ||||
| Earnings from Discontinued Operations | -- | ||||
| Extraordinary Item & Accounting Change | -- | ||||
| Minority Interest in Earnings | -- | ||||
| Net Income | -53.51% | ||||
| EBIT | -49.12% | ||||
| EBITDA | -48.86% | ||||
| EPS Basic | 65.47% | ||||
| Normalized Basic EPS | 65.47% | ||||
| EPS Diluted | 65.47% | ||||
| Normalized Diluted EPS | 65.47% | ||||
| Average Basic Shares Outstanding | 344.62% | ||||
| Average Diluted Shares Outstanding | 344.62% | ||||
| Dividend Per Share | -- | ||||
| Payout Ratio | -- | ||||